Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Mayne Pharma Group Limited
  6. News
  7. Summary
    MYX   AU000000MYX0

MAYNE PHARMA GROUP LIMITED

(MYX)
  Report
End-of-day quote. End-of-day quote Australian Stock Exchange - 09/21
0.29 AUD   +1.75%
09/21MAYNE PHARMA : 22/09/2021 FDA Approves Lexette® for Adolescent Plaque Psoriasis
PU
09/02MAYNE PHARMA : Change of Director's Interest Notice
PU
08/27MAYNE PHARMA : 2021 Full Year Media Release
PU
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Mayne Pharma Group Limited and Mithra Pharmaceuticals, Sa Announces Availability of Nextstellis Oral Contraceptive in Us

06/20/2021 | 06:26pm EDT

Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA announced the US commercial launch of NEXTSTELLIS® (3 mg drospirenone and 14.2 mg estetrol (E4) tablets), a new oral contraceptive with a novel estrogen having a unique mechanism of action. NEXTSTELLIS was approved by the FDA in April 2021 and is the first and only pill containing E4, a natural estrogen produced during pregnancy that is now synthesised from a plant source. E4 is the first new estrogen introduced in the US in over 50 years. NEXTSTELLIS will compete in the short-acting combination hormonal contraceptive (estrogen and progestin) market which is valued at US$3.5 billion1. Nearly 10 million American women use combination oral contraceptives, patches or vaginal rings every day. Of these contraceptives, more than 99% contain ethinyl estradiol, a synthetic estrogen that binds widely to all estrogen receptors in the body. E4 acts differently than other estrogens and is the first natural estrogen with selective action in tissues focusing on those needed to support contraceptive efficacy, cycle control, and other beneficial effects of estrogen. Its unique pharmacologic profile includes excellent oral bioavailability and a long half-life2.


© S&P Capital IQ 2021
All news about MAYNE PHARMA GROUP LIMITED
09/21MAYNE PHARMA : 22/09/2021 FDA Approves Lexette® for Adolescent Plaque Psoriasis
PU
09/02MAYNE PHARMA : Change of Director's Interest Notice
PU
08/27MAYNE PHARMA : 2021 Full Year Media Release
PU
08/27MAYNE PHARMA : 2021 Full Year Investor Presentation
PU
08/27MAYNE PHARMA : Appendix 4E and Statutory Accounts
PU
08/27MAYNE PHARMA : Widens Net Loss in FY21 on Higher Impairments
MT
08/26MAYNE PHARMA : 27/08/2021 Mayne Pharma 2021 Full Year Results Media Release
PU
08/26Mayne Pharma Group Limited Reports Earnings Results for the Full Year Ended June 30, 20..
CI
08/26MAYNE PHARMA : board renewal and new Chairman
PU
08/26Mayne Pharma Group Limited Announces Board Changes
CI
More news
Financials
Sales 2022 463 M 335 M 335 M
Net income 2022 -26,1 M -18,9 M -18,9 M
Net Debt 2022 259 M 188 M 188 M
P/E ratio 2022 -15,0x
Yield 2022 -
Capitalization 512 M 370 M 371 M
EV / Sales 2022 1,67x
EV / Sales 2023 1,36x
Nbr of Employees 967
Free-Float 77,2%
Chart MAYNE PHARMA GROUP LIMITED
Duration : Period :
Mayne Pharma Group Limited Technical Analysis Chart | MYX | AU000000MYX0 | MarketScreener
Technical analysis trends MAYNE PHARMA GROUP LIMITED
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Last Close Price 0,29 AUD
Average target price 0,42 AUD
Spread / Average Target 45,5%
EPS Revisions
Managers and Directors
Scott Richards Chief Executive Officer, MD & Executive Director
Peter Paltoglou Chief Financial Officer
Roger Campbell Corbett Independent Non-Executive Chairman
Gerard G. Nahum Chief Medical Officer
Keith Moore Vice President-Research & Development